BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
-4.98%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.46B
AUM Growth
-$155M
(-4.3%)
Cap. Flow
+$75.4M
Cap. Flow
% of AUM
2.18%
Top 10 Holdings %
Top 10 Hldgs %
66.74%
Holding
34
New
4
Increased
12
Reduced
7
Closed
2
Top Buys
| 1 |
TSRO
TESARO, Inc.
TSRO
|
$35.4M |
| 2 |
Esperion Therapeutics
ESPR
|
$30.2M |
| 3 |
Nektar Therapeutics
NKTR
|
$25.6M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$23.8M |
| 5 |
Exelixis
EXEL
|
$22.8M |
Top Sells
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$49.8M |
| 2 |
Agios Pharmaceuticals
AGIO
|
$28.4M |
| 3 |
Gilead Sciences
GILD
|
$21.3M |
| 4 |
Prothena Corp
PRTA
|
$14.7M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$12.7M |
Sector Composition
| 1 | Healthcare | 94.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MYOK
26
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $23.8M | 0.69% |
+480,000
| New | +$23.8M |
|
|
27
Exelixis
EXEL
$9.95B
| $22.8M | 0.66% |
+1,060,000
| New | +$22.8M |
|
|
FPRX
28
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $15.5M | 0.45% |
977,500
| – | – |
|
|
GTHX
29
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $15.3M | 0.44% |
+352,607
| New | +$15.3M |
|
30
Cidara Therapeutics
CDTX
$1.61B
| $11.9M | 0.34% |
114,764
| – | – |
|
31
Novavax
NVAX
$1.2B
| $11.2M | 0.32% |
416,500
| – | – |
|
|
ACHN
32
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $3.62M | 0.1% |
1,279,340
| – | – |
|
|
33
Prothena Corp
PRTA
$452M
| – | – |
-400,000
| Closed | -$14.7M |
|
|
AVXS
34
DELISTED
AveXis, Inc. Common Stock
AVXS
| – | – |
-402,800
| Closed | -$49.8M |
|